Dorzolamide - NDSRI's
References
FAQ's
References
- Baldwin, John J.; Ponticello, Gerald S.; Christy, Marcia E., Antiglaucoma thieno-thiopyran and thieno-thiepin sulfonamide derivatives, compositions, and method of use thereof, Merck and Co., Inc., United States, US4677115A, June 30, 1987
- Constanzer, M. L.; Chavez, C. M.; Matuszewski, B. K., Low level determination of dorzolamide and its de-ethylated metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry, Journal of Pharmaceutical and Biomedical Analysis, Volume: 15, Issue: 7, Pages: 1001-1008, 1997
Frequently Asked Questions
Can Dorzolamide impurities be removed or reduced during the manufacturing process?
Efforts are made during the manufacturing process of Dorzolamide to minimize impurity formation. Techniques such as purification, filtration, and optimization of reaction conditions help to remove or reduce impurities. Further, appropriate storage and packaging practices can maintain the drug's quality and minimize impurity formation.
Are there specific impurities in Dorzolamide?
The common impurities in Dorzolamide include related compounds formed during the synthetic process, degradation products resulting from exposure to light, heat, or moisture, and residual solvents used in manufacturing.
Which solvent helps in the analysis of Dorzolamide impurities?
Methanol is a solvent used in analyzing many impurities in Dorzolamide.
What are the temperature conditions required to store Dorzolamide impurities?
Dorzolamide impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.